The Controlled Release Drug Delivery Market is predicted to attain a size of over USD 49.48 Billion and market will thrive at a CAGR of 10.60 % during the forecast period
Controlled Release Drug Delivery Market Overview:
The Controlled Release Drug Delivery Market is expected to reach USD 49.48 Billion by 2030 at 10.60% CAGR during the forecast period 2022-2030. Controlled release medication delivery is used to provide a constant number of drug doses for a certain therapy. The strategy has various advantages, including lowering toxins buildup due to high dosages, reducing the frequency of medication delivery, improving patient compliance, and stabilizing medical conditions.
The global market for controlled release medicine delivery has expanded dramatically in recent years. The growing elderly and pediatric populations throughout the world are primarily responsible for the market's expansion. Furthermore, factors such as increased government regulation to minimize overdose effects and the rising frequency of chronic illnesses globally are expected to favorably affect market growth.
Controlled Release Drug Delivery Market Segmentation:
The Controlled Release Drug Delivery Market is segmented on the basis of route of administration, release mechanism, products, and End Users.
By route of administration the market is segmented into oral, injectable, ocular, nasal, topical and implantable. The injectable is sub-segmented into targeted delivery, transmucosal, and transdermal. On the basis of the release mechanism, the market is segmented into polymer-based drug delivery systems, micro-reservoir partition-controlled drug delivery systems, feedback-regulated drug delivery systems, activation modulated drug delivery systems, and chemically activated controlled drug delivery systems. The activation modulated drug delivery systems are sub-segmented into osmotic pressure activated drug delivery, hydrodynamic pressure activated drug delivery, vapor pressure activated drug delivery, mechanically activated drug, magnetically activated drug. The chemically activated controlled drug delivery systems are sub-segmented into pH-activated drug delivery, hydrolysis activated drug delivery, enzyme activated drug delivery.
By product, the market is segmented into metered dose inhalers, needle-free injectors, auto-injectors, nasal sprays, transdermal patches, nebulizers, infusion pumps, drug-eluting stents, sustained release, and ocular implants. By end user, the market is segmented into hospital and clinics, personal use, research centers, and others.
On the basis of region, the Global Controlled Release Drug Delivery Market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Some of the key players in the Global Controlled Release Drug Delivery Market are Depomed, Inc. (US), Coating Place, Inc.(US), Corium International Inc.(US), Alza Corporation (Johnson & Johnson)(US), Pfizer Inc.(US), SKY Pharmaceuticals Pvt. Ltd.(China), AstraZeneca (US),Biogen (US), GlaxoSmithKline (UK), Novartis (UK), Allergan (Ireland), Collegium Pharmaceutical (US) and Others.
Regional Market Summary Global Controlled Release Drug Delivery Market Share (%), by Region, 2017
Sources: National Cancer Institute, Cancer Research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of Health
It is estimated that North America is expected to dominate the Global Controlled Release Drug Delivery Marketduring the forecasted period owing to the increasing prevalence of various disease such as gastrointestinal diseases (Crohn's disease and ulcerative colitis), Alzheimer’s etc., advance infrastructure in pharmaceutical industry, increasing research and development activity, and presence of big pharmaceutical companies in the region. According to the Centers for Disease Control and Prevention, estimated that 3 million of the US adults were diagnosed with inflammatory bowel disease (either ulcerative colitis or Crohn’s disease) in 2015. Such a high number of patients with gastrointestinal diseases may increase the demand for controlled release drug.
Europe stood second largest in the Controlled Release Drug Delivery Market due to the increasing prevalence of respiratory diseases, high blood pressure or hypertension among the population. The Public Health England 2017 reported that around 2.1 million of the population below the age of 45 had high blood pressure in England in 2015. The increasing prevalence of hypertension and the cases of chronic diseases can boost the market during the forecasted period.
Asia-Pacific was anticipated to be the rapidly growing region for the controlled release drug delivery market. The market is likely to witness growth due to the increase in geriatric and pediatric population resulting in increasing demand for controlled doses to reduce the side effects and toxicity level in the patients. These factors may contribute to the market growth of controlled release drug in Asia-Pacific countries.
The Middle East and Africa holds low share in the global controlled release drug delivery market due to a fewer pharmaceutical industry with manufacturing units, low expenditure on healthcare, less awareness about the diseases and its treatments. However, the market is expected to observer growth due to increasing government funding on healthcare in the Middle East region.
Depomed, a specialist pharmaceutical firm based in Newark, California, has announced a reorganization plan that would cut employment by around 40% to approximately 70 people. The decision followed Depomed's agreement to sell its long-acting opioid Nucynta (tapentadol) to Collegium Pharmaceutical, located in Canton, Massachusetts. Depomed paid $1.05 billion to Janssen Pharmaceuticals, a division of Johnson & Johnson, for the US rights to the Nucynta franchise in April 2015. Depomed's medication revenue was $281.3 million in 2016.
Corium International is a privately held firm that specializes in the research, development, and production of sophisticated transdermal medication delivery technologies and solutions. Corium has created a variety of active and passive transdermal medicines with superior therapeutic or safety characteristics using its patented delivery technology and development and manufacturing capabilities. Corium also offers multiple partner-funded items in various phases of development with small, medium, and major pharmaceutical firms, spanning from manufacturing to research and development.
Segmentation and Key Market Players:
Controlled Release Drug Delivery Market, by Route of Administration:
Controlled Release Drug Delivery Market, by Release Mechanism:
Controlled Release Drug Delivery Market, by Products:
Controlled Release Drug Delivery Market, by End Users:
Controlled Release Drug Delivery Market, by Region: